Adaptive Biotechnologies Corp (ADPT)


Stock Price Forecast

Feb. 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adaptive Biotechnologies Corp chart...

About the Company

we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and

$143M

Total Revenue

831

Employees

$601M

Market Capitalization

-2.95

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADPT News

Adaptive Biotechnologies: A Post Earnings Assessment

4d ago, source: Seeking Alpha

Today, we circle back on diagnostic concern Adaptive Biotechnologies Corporation, which recently posted its fourth quarter ...

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

15d ago, source: Business Insider

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript

15d ago, source: Seeking Alpha

Thank you for standing by and welcome to the Adaptive Biotechnologies Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.

Adaptive Biotechnologies: Q4 Earnings Snapshot

16d ago, source: SFGate

SEATTLE (AP) — SEATTLE (AP) — Adaptive Biotechnologies Corp. (ADPT) on Wednesday reported a loss of $69.4 million in its fourth quarter. The Seattle-based company said it had a loss of 48 ...

Q4 2023 Adaptive Biotechnologies Corp Earnings Call

15d ago, source: Yahoo Finance

Chad Robins; Chairman of the Board, Chief Executive Officer, Co-Founder; Adaptive Biotechnologies Corp Tycho Peterson; Chief Financial Officer; Adaptive Biotechnologies Corp Susan Bobulsky; SVP, ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript

14d ago, source: Insider Monkey

Tycho Peterson: But we have the same data that ias you did at that DLBCL represents about 50, 50 plus 50% to 60% of all NHL. So that is one area as we mentioned that we’re going to be ...

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

15d ago, source: Stockhouse

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript

14d ago, source: Insider Monkey

Maybe if I can pull it a little further on the MRD Pharma side, obviously, solid backlog there, but could you maybe talk about the trends you guys are seeing that’s specific to Adaptive?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript

14d ago, source: Yahoo Finance

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript February 14, 2024 Adaptive Biotechnologies Corporation beats earnings expectations. Reported EPS is $-0.3, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...